STOCK TITAN

Nutriband Inc - NTRB STOCK NEWS

Welcome to our dedicated page for Nutriband news (Ticker: NTRB), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.

Nutriband Inc (NTRB) is a pharmaceutical innovator focused on transdermal drug delivery systems and abuse-deterrent technologies designed to enhance medication safety. This page serves as the definitive source for official company announcements, financial updates, and strategic developments.

Investors and industry stakeholders will find timely updates on AVERSA technology advancements, regulatory milestones, partnership agreements, and product pipeline progress. Our curated news collection ensures access to verified information directly impacting Nutriband’s market position and contributions to opioid safety solutions.

Key content includes earnings reports, intellectual property updates, manufacturing collaborations, and research breakthroughs. Bookmark this page to monitor Nutriband’s progress in developing transdermal therapies that address critical public health challenges while maintaining compliance with global regulatory standards.

Rhea-AI Summary

Nutriband Inc. (NASDAQ:NTRB) has received a Notice of Allowance from the USPTO for its AVERSA™ trademark, a key component of its abuse-deterrent transdermal patch technology. The company's lead product, AVERSA™ Fentanyl, is progressing towards commercial manufacturing scale-up in partnership with Kindeva Drug Delivery. Nutriband plans to file an IND application with the FDA, preceding pivotal studies to demonstrate the abuse-deterrent properties of AVERSA™ Fentanyl.

The upcoming human abuse potential study will compare AVERSA™ Fentanyl to a current fentanyl patch without abuse-deterrent features. Preliminary studies indicate AVERSA™ technology's high resistance to manipulation. A market analysis projects potential peak annual U.S. sales of $80 million to $200 million for AVERSA™ Fentanyl, highlighting its significant market potential in abuse-deterrent pharmaceuticals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.43%
Tags
none
-
Rhea-AI Summary

Nutriband has provided an update on its Aversa Fentanyl product development program. The company, in collaboration with Kindeva Drug Delivery, has progressed in developing the commercial manufacturing process for a transdermal fentanyl patch incorporating Nutriband's AVERSA™ abuse-deterrent technology. This follows a feasibility agreement and a commercial development and clinical supply agreement between the two companies.

Kindeva has validated analytical methods for handling aversive agents required for the product. Nutriband plans to file an Investigational New Drug (IND) application with the FDA, including chemistry, manufacturing, and clinical study protocols for a Phase 1 human abuse potential study, which is pivotal for the New Drug Application (NDA) process. No Phase 2 or Phase 3 trials are needed.

The AVERSA Fentanyl patch aims to prevent drug misuse while ensuring accessibility for patients in need, with potential peak annual US sales estimated between $80 million to $200 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.18%
Tags
none
-
Rhea-AI Summary

Nutriband reported Q1 revenues of $408,532, highlighting a 219% YoY increase in sports tape sales via its Pocono Pharma subsidiary. The company is leveraging penetration pricing to secure deals with major brands like KT Tape, Reebok, Adidas, and New Balance.

In Q1, Nutriband completed an $8.4M private placement at $4 per share, bringing its cash position to $8,347,739 as of April 30, 2024.

The company is advancing its AVERSA line, targeting a Q1 2025 NDA filing for AVERSA Fentanyl, projected to achieve peak annual sales of $80-$200M. AVERSA Buprenorphine could reach up to $130M in annual sales.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.03%
Tags
none
Rhea-AI Summary

Nutriband (NASDAQ:NTRB), a developer of transdermal pharmaceuticals and technology, will host an exclusive live investor webinar on May 30, 2024, at 4:15 p.m. ET.

Organized by RedChip Companies, the event will feature Chairman Serguei Melnik and CEO Gareth Sheridan, who will provide insights into the company's current operations and future milestones.

Investors can register for the free webinar and submit questions beforehand or during the live session.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
none
-
Rhea-AI Summary

Nutriband announced the appointment of Sergei Glinka to its board of directors. Glinka, an experienced business leader, brings a wealth of experience from his roles in major European companies. The Glinka family has invested $4.5 million in Nutriband via a private placement in April 2024, which totaled $8.4 million. Nutriband aims to use these funds to complete the FDA approval process for its AVERSA™ technology. AVERSA™, currently patented in 45 countries, is projected to reach peak annual US sales between $80 million and $200 million. The global opioid market was valued at $22.8 billion in 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.53%
Tags
management
-
Rhea-AI Summary

RedChip Companies will air interviews with Can-Fite BioPharma (NYSE American:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Money™ show on Bloomberg TV. Pnina Fishman, Executive Chairperson and Chief Scientific Officer of Can-Fite BioPharma, discusses the company's advanced clinical stage drug development focusing on oncology and inflammatory diseases. Can-Fite has two drug candidates in advanced stages of development with registration plans agreed with the U.S. FDA and the EMA. Gareth Sheridan, Founder and CEO of Nutriband, talks about their AVERSA™ abuse-deterrent transdermal technology to address the global opioid crisis. Nutriband's lead product, AVERSA™ Fentanyl, is targeting peak annual sales of $80 million to $200 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Nutriband Inc. announced the closing of an $8.4 million private placement to fund the commercial development of AVERSA Fentanyl, an abuse-deterrent opioid patch. The company aims to reach peak annual US sales of $80 million to $200 million. Nutriband is working with Kindeva Drug Delivery to develop the commercial manufacturing process for the product. The development milestones include FDA IND filing, pivotal human abuse potential clinical study, and NDA filing. The company targets Q1 of 2025 for NDA submission. Nutriband's AVERSA technology shows promising abuse-deterrent properties in preliminary studies. The company plans to file a 505(b)(2) NDA based on a single Phase 1 human abuse potential clinical study, potentially receiving expedited FDA review. Nutriband's pipeline includes abuse deterrent versions of fentanyl, buprenorphine, and methylphenidate transdermal patches.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.15%
Tags
none
-
Rhea-AI Summary
Nutriband Inc. has signed an exclusive supplier agreement with Fit For Life Group, a major brand license holder, for the launch of a new product under one of their top brands. The agreement was fully executed on April 19, 2024. Nutriband's subsidiary, Active Intelligence, will serve as the manufacturer. Fit For Life Group, founded in 2016, is a prominent player in the fitness equipment and yoga accessories market, with a strong brand portfolio including Gaiam, Reebok, Adidas, New Balance, SPRI, and FILA. They target a wide range of consumers from beginners to professionals, with distribution through major retailers like Target, Walmart, Dick's Sporting Goods, and Amazon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
none
-
Rhea-AI Summary
Nutriband Inc. has announced an $8.4M private placement to fund the development of AVERSA™ Fentanyl and target FDA approval in Q1 2025. The company has entered into securities purchase agreements for the sale of 2,100,000 shares of common stock at $4 per share, with investors receiving warrants to purchase additional shares at $6.43 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
none
Rhea-AI Summary
Nutriband Inc. announces engagement with Fit For Life Group, a major brand license holder, for manufacturing innovative products. Fit For Life Group, a market leader in fitness equipment and yoga accessories, has partnered with Nutriband to create innovative products for a wide range of consumers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.96%
Tags
none
Nutriband Inc

Nasdaq:NTRB

NTRB Rankings

NTRB Stock Data

55.86M
3.30M
70.29%
2.1%
2.53%
Biotechnology
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
ORLANDO